Renovascular Hypertension: Diagnosis, Imaging, and Revascularization
A practical framework for distinguishing atherosclerotic renal artery stenosis from fibromuscular dysplasia, choosing between duplex, CTA, and MRA, monitoring renal function on RAAS blockade, and identifying the narrow subset of patients who benefit from stenting after CORAL.
Executive Summary
Pathophysiology and Epidemiology
Renovascular hypertension begins when reduced perfusion pressure to the juxtaglomerular apparatus triggers renin release, generating angiotensin II. Angiotensin II raises systemic vascular resistance directly, stimulates aldosterone-driven sodium retention, and promotes renal interstitial fibrosis. The hemodynamic consequences differ between unilateral and bilateral disease in ways that determine both presentation and treatment safety. In unilateral renal artery stenosis with a normal contralateral kidney, the contralateral kidney is exposed to the elevated systemic pressure and undergoes a pressure natriuresis that maintains relatively normal volume status; renin-driven hypertension dominates, and ACE inhibitors typically lower blood pressure without precipitating renal failure. In bilateral renal artery stenosis (or stenosis to a solitary functioning kidney), both kidneys are hypoperfused, sodium and water retention generate volume-dependent hypertension, and glomerular filtration becomes critically dependent on angiotensin II–mediated efferent arteriolar constriction; blocking that constriction with an ACE inhibitor or ARB causes the dramatic creatinine rise that is the diagnostic signature of bilateral disease.
Atherosclerotic renal artery stenosis accounts for approximately 90% of cases. Plaque typically affects the ostium and proximal third of the renal artery, often as an extension of aortic atherosclerosis. Risk factors mirror coronary disease: age >55, smoking, dyslipidemia, diabetes, and known atherosclerotic disease elsewhere. Among patients undergoing coronary angiography for any reason, 10–25% have incidental renal artery stenosis >50%; among those with peripheral arterial disease, the prevalence rises to 30–40%. Fibromuscular dysplasia accounts for the remaining ~10% and is a non-atherosclerotic, non-inflammatory arteriopathy of medium and small arteries. FMD typically affects women aged 15–50 (female-to-male ratio approximately 9:1), spares the ostium, classically produces the “string of beads” appearance in the distal two-thirds of the renal artery (medial fibroplasia, the most common subtype), and may also involve carotid, vertebral, and visceral arteries.
Ischemic nephropathy refers to the parenchymal injury and progressive loss of glomerular filtration that develop with chronic hypoperfusion, typically when stenosis exceeds 70%. Atrophy proceeds from tubular cell apoptosis and interstitial fibrosis rather than from a single ischemic infarct. Pickering syndrome, also called flash pulmonary edema syndrome, describes recurrent acute pulmonary edema in a patient with bilateral renal artery stenosis (or stenosis to a solitary functioning kidney) and severely impaired sodium handling; aggressive RAAS blockade and revascularization are both highly effective and the syndrome is one of the strongest indications to intervene.
Classification: Atherosclerotic vs Fibromuscular Dysplasia
Distinguishing ARAS from FMD is the single most consequential classification step in renovascular hypertension because it dictates both prognosis and the appropriateness of revascularization. ARAS is fundamentally an atherosclerotic disease that requires aggressive cardiovascular risk reduction (statin, antiplatelet, smoking cessation), whereas FMD is a primary arteriopathy where percutaneous angioplasty is often curative.
Atherosclerotic renal artery stenosis (ARAS)
ARAS typically presents in patients older than 55 with risk factors and findings of generalized atherosclerosis. Plaque begins at the ostium and proximal third of the renal artery (truly an aortic plaque that involves the renal ostium). Concomitant coronary, carotid, or peripheral arterial disease is the rule. Progression to occlusion occurs in approximately 5–10% per year of untreated lesions >60%, but progression to clinical end-stage renal disease attributable to RAS alone is uncommon. Two large randomized trials (CORAL, ASTRAL) showed that, for the average patient with stable atherosclerotic stenosis, stenting added no benefit over optimal medical therapy.
Fibromuscular dysplasia (FMD)
FMD is a non-atherosclerotic, non-inflammatory arteriopathy. The AHA/SCAI consensus describes two major angiographic subtypes:
- Multifocal FMD (“string of beads”): 80–90% of cases. Caused by medial fibroplasia. Affects mid-to-distal renal artery. Classically young to middle-aged women (F:M ~9:1).
- Focal FMD: 10–20% of cases. Single concentric or tubular stenosis. Often presents earlier, including in children. May affect intima or adventitia.
Older histologic classifications (medial fibroplasia, intimal fibroplasia, perimedial fibroplasia, periadventitial hyperplasia) have largely been replaced by the simpler angiographic dichotomy because biopsy is rarely available. Up to 65% of patients with renal FMD have additional involvement of carotid or vertebral arteries (FMD of those vessels can produce headache, pulsatile tinnitus, transient ischemic attacks, or spontaneous cervical artery dissection).
Clinical red flags for renovascular hypertension
| Red flag | Suggests | Strength |
|---|---|---|
| Cr rise >30% within 2 weeks of starting ACEi/ARB | Bilateral RAS or RAS to solitary kidney | Highly specific |
| Recurrent flash pulmonary edema (Pickering syndrome) | Bilateral RAS | Highly specific |
| Severe HTN onset <30 (especially female) | Fibromuscular dysplasia | Moderate |
| Severe HTN onset >55 with diffuse atherosclerosis | Atherosclerotic RAS | Moderate |
| Resistant HTN despite ≥3 drugs incl. diuretic | RVH possible | Moderate |
| Abdominal bruit (especially systolic-diastolic) | RAS (low sensitivity, ~40%) | Moderate |
| Asymmetric kidney size >1.5 cm on imaging | Unilateral RAS with atrophy of stenotic side | Moderate |
| Hypokalemia despite no diuretic | Secondary aldosteronism from RAS | Suggestive |
Diagnostic Workup
The goal of imaging in suspected renovascular hypertension is to identify hemodynamically significant stenosis (typically >70% lumen narrowing or a translesional pressure gradient ≥10 mmHg) without exposing patients to unnecessary contrast or radiation. The choice of test depends on renal function, body habitus, and local expertise.
Renal artery duplex ultrasound (first-line)
Renal duplex is the preferred initial test in most centers because it is non-invasive, requires no contrast, and assesses both anatomy and hemodynamics. Diagnostic criteria vary slightly by laboratory but the most widely accepted thresholds are:
- Peak systolic velocity (PSV) >180–200 cm/s in the renal artery suggests >60% stenosis.
- Renal-aortic ratio (RAR) >3.5 (PSV in renal artery / PSV in aorta) supports significant stenosis.
- Resistive index >0.80 in the parenchyma predicts poor response to revascularization (suggests irreversible parenchymal disease).
- Tardus-parvus pattern (slow upstroke and low amplitude) in segmental or interlobar arteries distal to stenosis is corroborative.
Sensitivity 85–90%, specificity 85–95% in experienced hands. Operator-dependent; obesity, bowel gas, and accessory renal arteries are common limitations.
CT angiography (CTA) and MR angiography (MRA)
CTA offers excellent spatial resolution (sensitivity ~94%, specificity ~93%) and visualizes plaque calcification, accessory arteries, and aortic morphology. Limitation: iodinated contrast risk in patients with eGFR <30 mL/min/1.73 m². MRA with gadolinium has comparable sensitivity (~90%) but is contraindicated when eGFR <30 due to nephrogenic systemic fibrosis risk; non-contrast MRA techniques (time-of-flight, phase-contrast) underperform contrast-enhanced sequences. CTA is preferred when planning intervention because it characterizes plaque morphology and measures lumen diameter with sub-millimeter precision.
Captopril renography
Largely historical; rarely used now in centers with modern duplex/CTA capability. Principle: ACE inhibition unmasks the angiotensin II–dependent maintenance of GFR in the stenotic kidney, producing asymmetric uptake or delayed clearance of 99mTc-MAG3. Sensitivity drops sharply in bilateral disease, in renal insufficiency, and in patients on chronic ACEi. Reserved for the rare scenario where duplex and CTA/MRA are non-diagnostic.
Catheter angiography with translesional pressure gradient
Catheter angiography remains the gold standard for diagnosis but is reserved for cases where intervention is being considered or non-invasive imaging is non-diagnostic. A translesional pressure gradient ≥10 mmHg (resting) or a hyperemic gradient ≥20 mmHg is the hemodynamic threshold that defines a significant lesion. Visual stenosis estimation alone overestimates significance; pressure measurement should accompany planned intervention.
| Test | Sensitivity | Specificity | Best Use |
|---|---|---|---|
| Renal duplex US | 85–90% | 85–95% | Initial screen; serial follow-up |
| CTA | ~94% | ~93% | Pre-intervention anatomy if eGFR ≥30 |
| MRA (Gd) | ~90% | ~90% | Avoid iodinated contrast; eGFR ≥30 |
| Captopril renography | 60–75% | 80–90% | Rarely used; non-diagnostic anatomic studies |
| Catheter angiography + gradient | Reference | Reference | Pre-intervention; gradient ≥10 mmHg |
Medical Management
Medical therapy is the cornerstone of treatment for almost all patients with atherosclerotic renal artery stenosis and the bridge therapy for FMD before angioplasty. The CORAL trial enrolled 947 patients with hemodynamically significant ARAS (PSV >300 cm/s or angiographic stenosis >60%) and resistant hypertension or chronic kidney disease, randomized them to medical therapy alone vs medical therapy plus stenting, and after a median 43-month follow-up showed no difference in the composite of cardiovascular and renal events. The medical regimen used in CORAL is essentially the standard of care for ARAS today.
RAAS blockade and the creatinine/potassium safety check
ACE inhibitors and ARBs are the first-line antihypertensive agents in renovascular hypertension because angiotensin II is the principal driver of the elevated blood pressure. They are safe and effective in unilateral renal artery stenosis. In bilateral disease (or stenosis to a solitary kidney), they may precipitate acute kidney injury by removing the angiotensin II–dependent efferent arteriolar tone that maintains glomerular filtration; a creatinine rise of 10–20% within 1–2 weeks is acceptable and even reflects appropriate RAAS blockade, but a rise >30% should prompt suspicion of bilateral disease and consideration of imaging.
| Drug | Starting dose | Target | Monitoring |
|---|---|---|---|
| Lisinopril | 5–10 mg PO daily | 40 mg daily | Cr, K+ at 1–2 weeks; >30% Cr rise → investigate |
| Losartan | 25–50 mg PO daily | 100 mg daily | Same as ACEi; alternative if cough/angioedema |
| Amlodipine | 5 mg PO daily | 10 mg daily | Add-on; useful when RAAS blockade limited |
| Chlorthalidone | 12.5 mg PO daily | 25 mg daily | Preferred thiazide-like; check Na+, K+ |
| Spironolactone | 12.5–25 mg PO daily | 50 mg daily | Add-on for resistant HTN; K+ at 1 week |
| Hydralazine | 25 mg PO TID | 100 mg TID | For severe resistant HTN |
Other components of the medical regimen
- Statin: high-intensity statin (atorvastatin 40–80 mg PO daily or rosuvastatin 20–40 mg PO daily) for all ARAS patients regardless of baseline LDL; statins also slow stenosis progression.
- Antiplatelet: aspirin 81 mg PO daily for ARAS (cardiovascular risk reduction).
- Smoking cessation: critical in ARAS and FMD (smoking accelerates both).
- BP target: <130/80 per ACC/AHA 2017 in patients with cardiovascular disease, diabetes, or CKD — which describes most ARAS patients.
- Diabetes control: HbA1c <7% (individualized).
- Salt restriction: <2.3 g sodium daily; especially important in bilateral disease where volume retention dominates.
When to Revascularize
The two large randomized trials of stenting in atherosclerotic renal artery stenosis — ASTRAL (806 patients, 5-year follow-up) and CORAL (947 patients, 43-month median follow-up) — both showed that stenting added to optimal medical therapy did not reduce the rate of clinical events compared with medical therapy alone in patients with stable disease. Important caveats: both trials excluded the patients most likely to benefit from intervention (Pickering syndrome with recurrent flash pulmonary edema, severe rapidly progressive renal failure attributable to RAS, refractory hypertension despite maximal medical therapy). Current AHA/ACC and SCAI guidelines therefore restrict stenting to a narrow subset of patients in whom medical therapy clearly fails or is impossible.
Indications for revascularization
| Indication | Class of evidence | Notes |
|---|---|---|
| FMD with hypertension | Class I (PTA) | Plain balloon angioplasty; cure rate ~50%, improvement ~80% |
| Recurrent flash pulmonary edema (Pickering syndrome) | Class I (stent) | Bilateral disease or solitary kidney |
| True resistant HTN despite ≥3 drugs incl. diuretic + maximal RAAS | Class IIa (stent) | Document medication adherence first |
| Progressive bilateral RAS with rising Cr | Class IIa (stent) | Avoid in advanced parenchymal disease (RI >0.80) |
| Stable atherosclerotic RAS with controlled BP | Class III (no benefit) | CORAL/ASTRAL evidence |
| Asymptomatic incidental stenosis <70% | Class III (no benefit) | Optimize medical therapy |
Procedural choices
- FMD: percutaneous transluminal angioplasty (PTA) without stenting is the procedure of choice; stents are reserved for flow-limiting dissection. Cure of hypertension achieved in approximately 35–50% of FMD patients (more likely with shorter HTN duration), with improvement in another 30–40%.
- ARAS: percutaneous angioplasty with stenting (bare-metal or drug-eluting) when intervention is indicated. Surgical revascularization (aorto-renal bypass, endarterectomy) is now rarely performed and is reserved for cases requiring concurrent aortic surgery or when endovascular access fails.
- Embolic protection devices: not routinely required but considered in lesions with bulky proximal plaque to reduce atheroembolic AKI.
Special Populations
Pediatric renovascular hypertension
RVH accounts for 5–10% of secondary hypertension in children. Most cases are FMD, mid-aortic syndrome, Takayasu arteritis (especially Asian populations), neurofibromatosis type 1 (NF1; renal artery stenosis in ~25% of NF1 patients with HTN), or William syndrome. Diagnostic workup parallels adults but with attention to ionizing radiation (favor MRA over CTA), and revascularization (PTA) is the preferred long-term solution to avoid lifelong polypharmacy.
Takayasu arteritis
Inflammatory large-vessel vasculitis that may produce ostial renal artery stenosis through aortitis with extension. Treat the underlying disease first with high-dose corticosteroids (prednisone 1 mg/kg PO daily) and a steroid-sparing agent (methotrexate, azathioprine, or biologics such as tocilizumab). Defer angioplasty until inflammation is quiescent (ESR/CRP normalized), as intervention during active inflammation has high restenosis rates.
Renal artery stenosis in transplant kidney
Transplant renal artery stenosis (TRAS) develops in 1–10% of kidney transplants, typically in the first year, and presents with worsening hypertension, allograft dysfunction, and edema. Duplex thresholds are similar to native arteries. Angioplasty (with selective stenting for bail-out) is the treatment of choice. Avoid ACEi/ARB until anatomy is defined.
Pregnancy
FMD may be diagnosed during pregnancy when severe hypertension develops. ACEi/ARBs are contraindicated in all trimesters (teratogenic in 1st, fetal renal injury and oligohydramnios in 2nd/3rd). Use methyldopa, labetalol, or nifedipine for control. Defer revascularization until after delivery unless life-threatening uncontrolled HTN occurs.
Elderly patients with diffuse atherosclerosis
The temptation to “fix” an incidentally discovered lesion at the time of coronary or peripheral angiography is strong but should be resisted. Apply the CORAL/ASTRAL framework: optimize medical therapy first; intervene only for the indications listed in the table above.
Frequently Asked Questions
Practice Insights — Synthesized Patterns for Renovascular Hypertension Care
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across published practice patterns, clinicians have learned that the CORAL and ASTRAL trials reshaped this disease — but the referral pattern hasn’t caught up. Patients still arrive expecting an angioplasty, and the conversation is often more medical than procedural. The challenge is identifying the rare patient who genuinely benefits from revascularization while resisting the temptation to intervene on the much larger group who won’t. Below is how experienced clinicians actually approach this.
Three Red Flags Beat Imaging
The patients clinicians escalate fastest aren’t the ones with incidental renal artery stenosis on imaging — they are the ones with the three specific phenotypes that CORAL did NOT randomize. Flash pulmonary edema without LV dysfunction, abrupt AKI on starting ACE-i or ARB, and uncontrollable HTN despite 4+ agents at maximal doses. In practice, any one of these triggers an immediate work-up and a low threshold for revascularization. Without them, clinicians treat as resistant HTN and the renal arteries become an academic finding.
FMD Is Not Atherosclerotic
In experienced hands, the single biggest diagnostic mistake is lumping fibromuscular dysplasia with atherosclerotic renovascular disease. FMD is young, female, often presents with audible abdominal bruit, has the classic “string of beads” on angiography, and responds beautifully to balloon angioplasty WITHOUT stent — durable cure in many. Atherosclerotic disease is older, vascular comorbidity, ostial stenosis, and CORAL says medical therapy wins. Seasoned clinicians never apply the CORAL conclusions to an FMD patient; they are different diseases sharing a name.
Medical Therapy First — Period
The standard atherosclerotic RVHT workflow is: ACE-i or ARB (titrated cautiously with Cr/K+ monitoring at 1-2 weeks), thiazide-like diuretic (chlorthalidone), CCB, then 4th agent. Statin to LDL <70. Antiplatelet therapy. Smoking cessation. Tight BP target 130/80. Revascularization is the exception, not the rule, and the conversation with patients frames it that way from visit one. The “fix the stenosis and the BP will normalize” expectation is the single biggest source of disappointed referrals experienced practitioners see.
ACE-i + Bilateral Stenosis Is Not Always Forbidden
The textbook rule “no ACE-i if bilateral renal artery stenosis” leads to undertreatment. In experienced hands, clinicians will start a low-dose ACE-i in bilateral disease IF baseline creatinine is acceptable, IF the patient is monitored closely (Cr/K+ at 1, 2, and 4 weeks), and IF experienced clinicians can stop quickly if Cr rises >30%. The BP benefit usually outweighs the AKI risk in stable disease, and many bilateral-stenosis patients tolerate ACE-i without incident. The blanket prohibition deprives them of the best antihypertensive class for their condition.
Illustrative Scenario — A Case That Reset The Revascularization Threshold
(Composite teaching scenario assembled from published patterns; not an individual patient.)A woman in her early 70s was referred for “bilateral renal artery stenosis on CT, BP 178/96 on three drugs — please stent.” Her atherosclerotic disease was ostial, bilateral 70% stenosis. Importantly, both kidneys were normal size (no atrophy), no flash pulmonary edema history, no ACE-i intolerance, and her recent eGFR had been stable. The treating clinicians declined revascularization, restructured her regimen to ramipril 10 mg + chlorthalidone 25 mg + amlodipine 10 mg + spironolactone 25 mg, added atorvastatin 40 mg and aspirin 81 mg, and brought her BP to 132/78 within 8 weeks with stable Cr. Eighteen months later her BP remains controlled, her renal function is unchanged, and no intervention has been done.
Practice Pattern Refinements Beyond the Standard Guideline
- Doppler ultrasound as first-line, CTA as confirmation. In practice, the screening test is duplex Doppler — non-invasive, no contrast, no radiation. CTA or MRA is reserved for confirming positive Doppler or evaluating anatomy for intervention. CT angiography as the first test in someone with mild renal dysfunction risks contrast nephropathy for a question that Doppler often answers.
- Mineralocorticoid receptor antagonist as 4th drug routinely. The PATHWAY-2 trial established spironolactone as the optimal 4th-line agent in resistant HTN. In experienced hands, this is more impactful than adding a fifth conventional agent in renovascular disease. clinicians add spironolactone 25-50 mg before considering revascularization in most refractory cases.
- Annual renal Doppler in known atherosclerotic disease. Seasoned clinicians follow these patients with annual or biennial Doppler to track progression of stenosis and kidney size. A shrinking kidney or worsening velocities prompts revascularization consideration that the BP alone might not. Functional decline is a smoldering indication.
- Decline the procedural request from referring physician with documentation. When a referral arrives requesting “renal artery angioplasty” without the clinical triggers, clinicians document the explicit reasoning for medical management — CORAL, ASTRAL, preserved kidney size, absence of flash edema/ACE-i intolerance — and copy the referring physician. This educates the network and prevents repeat referrals.
- Mitral Regurgitation: Primary vs Secondary, Imaging, and TEER Indications
- Hypertension — Diagnosis, Risk Stratification, and Pharmacotherapy
- Constrictive Pericarditis: Hemodynamic Diagnosis, Imaging Criteria, and Pericardiectomy Strategy
- Cardiac Tamponade: Beck’s Triad, Echocardiographic Diagnosis, and Emergency Pericardiocentesis Technique
- Aortic Regurgitation: ACC/AHA Diagnosis, Echo Severity Grading, and Surgical Timing
- Complete Heart Block: Diagnosis and Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- 2017 ACC/AHA Guideline for High Blood Pressure in Adults (Hypertension · 2018)